ARS PHARMACEUTICALS INC
SPRYNASDAQ🏆 #2001 by market capEarnings Aug 13 · PostUS Equity
$590.20▲ $32.70 (+5.54%)
Simulated price1h—
24h▲ 5.5%
7d—
14d—
30d—
1y—
🏦Market Cap
$848M
Small Cap
📈Revenue Growth (YoY)
+1.9%
Slowing
📊Gross Margin
74.1%
High
💵FCF Margin
—
⚖️P/S Ratio
8.6x
Elevated
Otter Score
62
Fair
No chart data available for SPRY.
Trading Snapshot
- Day Range
- $583.97 – $596.18
- 52-Week Range
- $6.66 – $18.90
- Volume
- $3.18B
- Avg Volume
- $2.44B
- Shares Outstanding
- 99.3M
- Next Earnings
- Sep 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $99M
- Last Q Revenue
- $26M
- P/E Ratio
- —
- P/S Ratio
- 8.6x
- EPS (TTM)
- $-2.00
- Dividend Yield
- —
Why Investors Own SPRY
- ✓High-growth profile — revenue up +12.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 36% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$99M▲ +10.3% YoY
Gross Margin (TTM)
36.4%▲ +0.2% YoY
Operating Income (TTM)
$23M▲ +10.3% YoY
Free Cash Flow (TTM)
$25M▲ +10.3% YoY
About ARS PHARMACEUTICALS INC
A company profile for ARS PHARMACEUTICALS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
62/100
Analyst Price Target
ⓘAverage Target
$673.89
▲ +14.2% Upside
High Target$798.27
Low Target$589.64
Based on 33 analysts
Latest News & Updates
🚀
Reuters·2h ago
ARS PHARMACEUTICALS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift SPRY price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
ARS PHARMACEUTICALS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.